Treatment algorithms for poor cytogenetic-risk myelodysplastic syndrome (MDS), defined by chromosome 7 abnormalities or complex karyotype (CK), include allogeneic stem cell transplantation (alloSCT). We studied outcome of alloSCT in chromosome 7 abnormal MDS patients as this data are scarce in literature. We specifically focused on the impact of the extra presence of CK and monosomal karyotype (MK). The European Group for Blood and Marrow Transplantation database contained data on 277 adult MDS patients with a chromosome 7 abnormality treated with alloSCT. Median age at alloSCT was 45 years. Median follow-up of patients alive was 5 years. Five-year progression-free survival (PFS) and overall survival (OS) were 22% and 28%, respectively. In multivariate analysis, statistically significant predictors for worse PFS were higher MDS stages treated, but not in complete remission (CR) (hazards ratio (HR) 1.7), and the presence of CK (HR 1.5) or MK (HR 1.8). Negative predictive factors for OS were higher MDS stages treated, but not in CR (HR 1.8), and the presence of CK (HR 1.6) or MK (HR 1.7). By means of the cross-validated log partial likelihood, MK showed to have a better predictive value than CK. The results are relevant when considering alloSCT for higher-stage MDS patients having MK including a chromosome 7 abnormality.
INTRODUCTION
Myelodysplastic syndrome (MDS) results from ineffective hematopoiesis causing one or more cytopenias. The International Prognostic Scoring System consists of several factors that together predict the speed of transformation to secondary acute myeloid leukemia (sAML) and death. The International Prognostic Scoring System factors include the percentage of blasts in bone marrow and blood, the number of cytopenias and specific karyotypic abnormalities. 1 Poor-risk karyotypic abnormalities are defined either as complex abnormalities (that is, X3 chromosomal abnormalities, complex karyotype (CK)) or as chromosome 7 abnormalities, both of which carry a poor prognosis in AML as well. 2, 3 Recently, monosomal karyotype (MK) was shown to be a more accurate predictor of poor outcome in AML. 4 The results of AML-like remission induction and consolidation therapies in MDS patients with advanced stages and poor-risk karyotypes are disappointing. Complete remission (CR) rates are low, and because of relapses, survival (OS) is almost 0% at longer follow-up. [5] [6] [7] [8] [9] [10] [11] Given this poor outcome, many patients are offered an allogeneic stem cell transplantation (alloSCT) because it is considered the only curative treatment. Unfortunately, many studies show that the presence of poor-risk karyotypes adversely affects outcome after alloSCT. 6, [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] However, the number of patients with poor karyotypic risk in these studies is very low, which prevents to draw firm conclusions. Only one prospective trial addressed the question whether outcome of poor-risk MDS patients treated with intensive chemotherapy followed by alloSCT was superior to consolidation with autologous SCT in a donor versus no donor comparison. 6, 23 No difference in OS was found in the first analysis of 117 evaluable patients, 6 but at longer followup, alloSCT predicted better progression-free survival (PFS) and OS. 23 Again, in this study, the number of patients with a poor-risk karyotype was low (n ¼ 29).
Other factors that predicted a poor outcome of MDS/sAML patients after alloSCT were age, time from diagnosis to alloSCT, blast percentage or remission state at alloSCT 15, 16, 21, 22, [24] [25] [26] [27] and prior remission-induction therapy, 28 although contradictory results have been reported. 13, 14, 29 To better estimate outcome of patients with cytogenetically high-risk MDS/sAML, we performed a retrospective analysis on patients with a chromosome 7 abnormality treated with alloSCT using the European Group for Blood and Marrow Transplantation (EBMT) database. In addition to the role of well-known risk factors, 30 we studied the impact of extra chromosomal instability defined as either CK or MK in addition to the presence of a chromosomal 7 abnormality. 1 Division of Hematology, Department of Internal Medicine, University Hospital Maastricht, MUMC, Maastricht, The Netherlands;
PATIENTS AND METHODS

Patient population
We interrogated the EBMT registry for MDS/sAML patients with chromosome 7 abnormalities and who had received an alloSCT for the first time either from related or unrelated donors. We selected only patients with known cytogenetics within 1 year before alloSCT, in an attempt to reduce the likelihood of clonal evolution. Chromosome 7 abnormalities were detected by metaphase karyotyping, FISH or both techniques. De novo AML was excluded from the analysis. Two-hundred and seventy-seven patients that fulfilled these criteria were extracted from the EBMT database.
Definitions
We defined disease status at alloSCT according to FAB 31 and remission status. Patients designated as RA/RARS never had a higher stage before alloSCT. Patients with higher MDS stages, that is, (refractory anemia with excess blasts) RAEB(t)/sAML, at any time point before alloSCT, were classified into three groups according to treatment with remissioninduction chemotherapy and its effect: CR, not in CR, and not pretreated. sAML is defined as AML arisen from lower-stage MDS or after previous cytotoxic therapy for unrelated diseases (that is, malignant or autoimmune diseases) Patients were categorized as having either a monosomy 7 or another chromosome 7 abnormality. CK was defined as the presence of X3 chromosomal abnormalities, 1 and MK as the presence of any autosomal monosomy accompanied by either X1 additional autosomal monosomies or X1 structural chromosomal abnormalities. 4 We defined the conditioning intensity as myeloablative or reduced intensity according to EBMT guidelines (www.ebmt.org/EBMT_Hand-book.html). Donors were either an human leukocyte antigen-identical sibling or an alternative donor. The latter group consisted of matched relatives other than siblings, mismatched relatives, matched unrelated and mismatched unrelated donors. The lack of high-resolution molecular human leukocyte antigen-typing data in the majority of patients precluded narrowing down the degree of mismatching accurately. Patient and donor sex mismatch was classified as described previously. 30 Cytomegalovirus status was classified according to patient and donor cytomegalovirus IgG status as published recently. 32 We defined PFS as OS without progressive disease. Disease progression refers to relapse in patients with RA/RARS or with higher stages in CR at alloSCT, and to progressive disease in higherstage patients that had no CR after remission induction or that had not received pretreatment. 33 Nonprogression mortality (NPM) is defined as death from any cause except progressive disease.
Statistical analysis
The duration of OS/PFS or time to disease progression and NPM was calculated from the day of alloSCT onwards. Disease progression and NPM were considered as competing events and were analyzed by means of cumulative incidence statistics. We used the two-tailed log-rank test to identify factors with statistically significant impact on OS and PFS, whereas the Gray test was used in the same way for disease progression and NPM. We applied multivariate Cox regression modeling to evaluate the predictive effect of baseline variables on NPM, progression, PFS and OS, and we focused specifically on the additional presence of CK or MK. All analyses were performed on a subset of patients with complete information on all variables introduced in the Cox model (n ¼ 243 for Cox models 1 and 2, and n ¼ 247 for all other Cox models). Baseline variables that are known to have predictive power on outcome after alloSCT in a large cohort of patients, 30 that is, age, remission status at alloSCT, donor type, sex match and cytomegalovirus match, were also introduced into our Cox models. We did not introduce time from diagnosis to transplant in the Cox model, first because this variable was found not to be of prognostic significance in a large EBMT cohort of MDS patients containing all cytogenetic-risk groups. 30 Moreover, in MDS, this variable is evidently correlated with a variety of other covariates like stage at diagnosis, the feasibility of adequate supportive care, age, performance and comorbidity and is therefore not informative by itself. Intensity of conditioning was not used in the Cox models because it bears no relationship to the impact of additional cytogenetic abnormalities on outcome. It was also not a predictor in earlier EBMT MDS studies, 34, 35 and its correlation with other (partly unknown) covariates like age, performance, comorbidity, MDS stage and application of pretreatment makes an estimation of its net effect impossible. We omitted year of transplantation 30 as this variable did not reveal any significance for PFS and OS in a preliminary Cox analysis with our data set, and because we wanted to focus on variables that can be used in clinical decision making for future patients. Variables indicating CK or MK, the presence of a single chromosome 7 abnormality or the accompaniment of extra chromosomal abnormalities were entered as shown in the tables. We validated the proportionality assumption of the model we used, to illustrate clinical relevance using a test based on scaled Schoenfeld residuals, and found that it did not have to be rejected for any of the covariates. For the purpose of plotting model-based PFS curves, a web-based OS visualization tool has been developed by H J van der Wijk (Department of Medical Statistics and Bioinformatics, Leiden University Medical Center, Leiden, the Netherlands, http://www.msbi.nl/SV/Chart.aspx?model=MvGMKCK&key= ss51zo4bjt). The reader can create our curves and similar ones with this tool. Calculations were performed using the Statistical Package for the Social Sciences (PASW Statistics, IBM, Armonk, NY, USA) software, version 18.0 (SPSS Inc., Chicago, IL, USA) and R version 2.12.2, with packages 'survival' and 'cmprsk' (http://www.r-project.org/foundation). We compared predictive performance (indicating how well the models predict the failure times for individual patients) of a subset of the Cox models for PFS by means of the cross-validated log partial likelihood (taking into account the optimism due to model fitting on a single sample) as implemented in the 'penalized' package in R. 36 P-values o0.05 were considered to be statistically significant.
RESULTS
Patient characteristics
Two-hundred and seventy-seven MDS/sAML patients with a recognized chromosome 7 abnormality within one year before alloSCT were identified from the EBMT database. The distribution of the various chromosomal subcategories, including CK and MK, is shown in Table 1 . One hundred and sixteen patients had chromosome 7 abnormalities other than monosomy 7. In 40 of these patients, the type of chromosome 7 abnormality was not specified. In those that were specified, 26 patients had a 7q deletion; 11 had t(1;7)(q10;p10); 12 had other translocations, and 5 Table 1 . Distribution of several kinds of extra chromosomal abnormalities in MDS patients with either a monosomy 7 ( À 7) or any other chromosome 7 abnormality (no À 7) treated with alloSCT
Single other chr.
7 abn. but no À 7 (n ¼ 70)
chr. 7 abn. and CK and MK (n ¼ 43)
Abbreviations: abn., abnormality; chr., chromosome; CK, complex karyotype; MDS, myelodysplastic syndrome; MK, monosomal karyotype. Data shown are of 261 patients as from 16 insufficient data were available in the database for proper classification in this way. The percentages indicate the distribution of the various chromosome 7 abnormalities, including the presence of CK and/or MK within the ' À 7' and the 'no À 7' subgroup.
Transplant outcome in chromosome 7 abnormal MDS M van Gelder et al had other chromosome 7 abnormalities. Twenty-two of the patients not having a monosomy 7 could be classified as having CK and/or MK. The median age at alloSCT was 45.2 years (range 18.1-67.5). Table 2 shows the distribution of the different variables used for the univariate and multivariate analyses, categorized according to the indicated different karyotypic abnormalities. Data shown are of 266 MDS patients with chromosome 7 abnormalities with complete data for classification based on various specific and/or extra chromosomal abnormalities. Of an additional four patients, disease status at alloSCT was unknown, and of two patients, stem cell source was unknown; recipient sex match and CMV IgG was unknown in 2 and 12 patients, respectively. The percentages indicate the distribution of the various chromosome 7 abnormalities, including the presence of CK and/or MK within every subgroup.
Transplant outcome in chromosome 7 abnormal MDS M van Gelder et al
Univariate analysis Median follow-up of patients who were still alive was 5 years (range 0-18 years). Estimated 5-year PFS and OS were 22 ± 6% (95% confidence interval) and 28±6%, respectively (Figure 1 ). The probability of disease progression at 3, 12 and 60 months was 9 ± 3%, 29 ± 5% and 38 ± 6%, respectively. NPM at 3, 12 and 60 months was 21 ± 5%, 36 ± 6% and 40 ± 6%, respectively. Results of univariate analysis for 5-year NPM, disease progression, PFS and OS are shown in Table 3 .
NPM: Lower age and myeloablative conditioning were associated with a higher NPM (P ¼ 0.004 and 0.03, respectively).
Disease progression: Lower age (P ¼ 0.007), disease status at alloSCT (P ¼ 0.06), CK (P ¼ 0.02) and MK (Po0.001) were associated with increased risk of progressive disease. SCT from human leukocyte antigen-identical siblings (P ¼ 0.04) and the use of peripheral blood stem cells (P ¼ 0.06) were also associated with increased disease progression.
PFS: Disease status at alloSCT (P ¼ 0.04), CK (P ¼ 0.01) and MK (Po0.001) was associated with decreased PFS.
OS: Disease status at alloSCT (P ¼ 0.02), CK (P ¼ 0.006) and MK (Po0.001) were associated with decreased OS.
Multivariate analyses
The focus of this analysis was to identify the cytogenetic abnormality with best predictive value for outcome. For this purpose we prepared several Cox models that differ in the cytogenetic subcategorization only.
Comparison of monosomy 7, the absence of monosomy 7, the presence of additional chromosomal abnormities and either CK or MK. We first studied the relative predictive impact of the presence of a monosomy 7 or of other chromosome 7 abnormalities, and of the presence of extra chromosomal abnormalities, including either CK (Table 4 , first Cox model) or MK (Table 4 , second Cox model), for PFS and OS. In both Cox models, there were no statistically significant differences between the different cytogenetic subcategories except for the presence of MK (hazards ratio (HR) 1.68, P ¼ 0.01 for PFS and HR 1.58, P ¼ 0.04 for OS).
Comparison of CK and no CK, or of MK and no MK. As Cox models with variables containing many subcategories are less stable, and because the hazard ratios for PFS and OS for the different values of the cytogenetic variables without either CK or MK were not statistically significantly different (Table 4) , we built two additional models with which we addressed the relative impact of the presence of CK or MK, respectively, for NPM, progression, PFS and OS (Table 5 , third and fourth Cox model, respectively).
NPM: Lower age was associated with a higher NPM (HR 0.97, Po0.001 in both models). Female donor for male patient was also associated with increased NPM (HR 1.73, P ¼ 0.03 and HR 1.83, P ¼ 0.02 in third and fourth model, respectively) as was patient cytomegalovirus IgG positivity (HR 1.79, P ¼ 0.05 in both models).
Disease progression: CK (HR 1.90, P ¼ 0.0005) and MK (HR 2.21, Po0.001) were associated with increased risk of progressive disease.
PFS: 'Higher stages, treated but not in CR' (HR 1.65, P ¼ 0.03) and CK (HR 1.51, P ¼ 0.02) were associated with decreased PFS in the third Cox model, whereas only MK (HR 1.82, Po0.001) was associated with decreased PFS in the fourth Cox model.
OS: Lower age was associated with decreased OS but the HR was only 0.99 (P ¼ 0.03 and 0.05 in the third and fourth Cox model, respectively). 'Higher stages, treated but not in CR' were associated with decreased OS in both the third and fourth Cox model (HR 1.81, P ¼ 0.02 and HR 1.75, P ¼ 0.02, respectively) as were CK (HR 1.63, P ¼ 0.004) and MK (HR 1.72, P ¼ 0.002). Female donor for male patient was also associated with decreased OS (HR 1.44, P ¼ 0.05).
MK is better predictive for PFS and OS than CK. To test more directly whether CK or MK was most predictive for outcome, we introduced both factors in a fifth Cox model. The HRs for PFS and OS were then only statistically significantly increased for MK and not for CK (data not shown). When an interaction between CK and MK was added, this term did not have a significant HR (data not shown). We then compared all Cox models for PFS (Cox models 3 and 4 and the fifth model with the interaction of CK and MK) by means of the cross-validated log partial likelihood. Of these, the model with only MK (model 4) performed best and that with only CK (model 3) performed worst (the difference in cross-validated log partial likelihood was 3.8). The clinical relevance for PFS from the increased hazard ratios for MK and the different disease stages at alloSCT is illustrated in the Cox model-based PFS curves (Figure 2 , corresponding to Cox model 4).
DISCUSSION
To the best of our knowledge, this is the first report on a large series of MDS/sAML patients with high-risk disease as defined by the presence of a chromosome 7 abnormality who had been treated with allogeneic SCT. In multivariate analysis, three factors had a statistically significant negative impact on PFS and/or OS in all models: lower age, 'higher stages, treated but not in CR' and the presence of extra chromosomal abnormalities that classify either for CK or MK.
Although the HR for age hardly differed from 1.0, its impact is illustrated when one calculates the HR for a 20-year difference in age at time of alloSCT. This HR will then be 0.99 20 ¼ 0.82. This difference resulted at least in part from a difference in NPM. This is in contrast to some previous reports on outcome of alloSCT in MDS/sAML patients where higher age was accompanied by a higher NPM. 15, 16, 25, 26 In other reports, however, age was not significantly predictive for any outcome parameter 12, 14, 17, 19, 22, 29, 37 or had not been evaluated by multivariate analysis. 13 The impact of younger age on NPM and OS may well be related to the fact that the study cohort only comprises patients with poor cytogenetic risk. In the presence of alleged confounders that are not retrievable from the EBMT database like comorbidity, poor performance and less-perfectly matched donors, treating physicians may be more inclined to accept the risks of alloSCT in younger patients.
In the multivariate analyses, the negative predictive power of MK was shown to be slightly higher than that of CK for PFS. The HRs of CK and MK for PFS and OS were fairly similar, because of the considerable overlap between patients having CK or MK. It is apparent that in the absence of CK or MK, HRs of the other cytogenetic subcategories for PFS and OS were (almost) p1.0.
Their PFS and OS seem to come close to that of patients with intermediate risk cytogenetics as was also reported in previous studies. 6, [12] [13] [14] [15] [16] [17] [18] [19] [21] [22] [23] 28, 37 We suppose that the negative impact of the classical poor-risk cytogenetic abnormalities in previously published studies on the effect of alloSCT in MDS patient cohorts, 6, [12] [13] [14] [15] [16] [17] [18] [19] 21, 22, 37 in fact, may just represent the poor risk of having CK or MK but not the mere presence of a chromosome 7 abnormality. The observed heterogeneity within the classical high cytogenetic risk group defined by the presence of a chromosome 7 abnormality may also explain why in a study on the effect of alloSCT in patients with RA/RARS high cytogenetic risk was not of prognostic impact. 34 Indeed, this group comprized only 41 RA/ RARS patients, of whom probably a low percentage had CK or MK. Our results are in line with a recent publication, showing that the original International Prognostic Scoring System chromosome risk classification needs to be reconsidered because of differential OS between, in this case, patients with particular chromosome 7 Abbreviations: abn., abnormality; alloSCT, allogeneic stem cell transplantation; À 7, monosomy 7; chr., chromosome; CK, complex karyotype; CMV, cytomegalovirus; MK, monosomal karyotype; NPM, nonprogression mortality; OS, overall survival; PFS, progression-free survival; sAML, secondary acute myeloid leukemia. The two-tailed log-rank test was used for identification of single factors with statistically significant impact on OS and PFS, whereas the Gray test was used for the same purpose for the outcome disease progression and NPM.
a These 17 patients with missing data include, besides the 12 mentioned in the variable 'MK absent or present' , 5 additional patients with ' À 7 þ extra abnormality, no MK' that were withdrawn from the analysis due to the low number of patients. Abbreviations: abn., abnormality; alloSCT, allogeneic stem cell transplantation; À 7, monosomy 7; chr., chromosome; CK, complex karyotype; CI, confidence interval; HR, hazards ratio; MK, monosomal karyotype; MDS, myelodysplastic syndrome; OS, overall survival; PFS, progression-free survival; sAML, secondary acute myeloid leukemia. Two Cox models, all based on 243 patients with complete covariate information, were fitted as indicated in the upper rows, for PFS as well as for OS. Shown are the results for the various cytogenetic subgroups and CK (model 1) or MK (model 2). a
The subgroup ' À 7 þ extra abnormality but no MK' was omitted because of the very low number of patients in this category (n ¼ 5). The variable in bold indicate statistical significance at the 5% level. Results for the other covariates (age, remission status at alloSCT, donor type, sex match and CMV match) are not shown for clarity reasons and because the results for these covariates are actually similar to the results in the third and fourth Cox models (Table 5) .
Transplant outcome in chromosome 7 abnormal MDS M van Gelder et al Table 5 . OS, overall survival; PFS, progression-free survival; sAML, secondary acute myeloid leukemia. The two Cox models were based on 247 patients with complete covariate information, and were fitted as indicated in the respective upper rows, for NPM, progression, PFS and OS. Variables in bold indicate statistical significance at the 5% level.
Transplant outcome in chromosome 7 abnormal MDS M van Gelder et al abnormalities and those with complex abnormalities that were treated with non-intensive supportive interventions. 38 In further studies in a nonselected group of MDS patients, we will test the hypothesis that PFS and OS after alloSCT without CK or MK is similar irrespective of the presence of a chromosome 7 abnormality. In addition, the impact of CK and MK on the absence of a chromosome 7 abnormality will be studied. 39 MDS patients with any chromosome 7 abnormality that received alloSCT without prior progression to a higher MDS stage than RA/RARS, or with higher stages in remission at transplantation, had the best outcome, especially, in the absence of CK or MK. The fact that outcome after alloSCT for lower-stage MDS is accompanied by better OS than that for higher stages is in accordance with other studies. [13] [14] [15] 17, 26, 34, [40] [41] [42] New is that this also holds true for the patients who up to now are considered to have a high risk due to a chromosome 7 abnormality. Also, new is the impact of additional CK or MK in these patients. Outcome (PFS and OS) of patients with higher stages than RA/RARS was worse, as reflected by higher HRs, although the difference was only statistically significant for patients with 'higher stages, treated but not in CR'. The value of MDS disease status at alloSCT differed substantially among each other in other studies. Some authors report that OS was superior for those transplanted in CR, whereas outcome was uniformly poor for those who either never received or who failed pretreatment. 16, 22, 24, 27, 28 Other studies show that outcome after successful remission induction is similar to outcome of untreated higher-stage MDS patients while unsuccessfully pretreated patients do worse, 13, 41, 43 or reveal that both higherstage MDS and induction treatment are independently associated with poor outcome (the latter because of a higher NPM). 13 In contrast, some studies showed no statistically significant differences in outcome whether MDS patients had been pretreated or not. 14, 44 In this context, it has to be taken into account that patients with poor-risk cytogenetics more often failed remission induction and, additionally, suffered more frequently from early relapse after AML-like chemotherapy. 8, 22 The role, if any, of remission induction before alloSCT in higherstage MDS remains to be elucidated. It also remains to be seen if the outcome of higher-stage poor-risk MDS patients is better with alloSCT than with conventional chemotherapy only. The only prospective study that addressed this issue suggests improved OS after alloSCT in classically defined poor cytogenetic-risk higherstage MDS patients, after successful remission induction. 23 However, the number of patients with and without CK/MK in this study is not known.
The relevance of our results for clinical decision making seems obvious. As illustrated in Figure 2 , PFS is seriously low in RAEB(t)/ sAML patients with chromosome 7 abnormalities having MK and Table 5 , Cox model 4). MK was introduced as the variable of interest as it appeared to have a somewhat stronger predictive impact on PFS than CK as discussed in the Results section. For all curves, age at alloSCT, donor type, cytomegalovirus (CMV) IgG serostatus and sex match were kept constant at median age (45.5 years), human leukocyte antigen (HLA)-identical sibling, donor and recipient both CMV IgG-negative, and no female donor for male patient, respectively. Predicted PFS for patients without MK is shown by the black lines, and for patients with MK by the gray lines. The reader can recreate these and similar curves through the web-based OS visualization tool described under Statistical analysis in the Patients and methods section. Transplant outcome in chromosome 7 abnormal MDS M van Gelder et al either being treated, but not in CR, or being untreated. Performing alloSCT in patients with these characteristics is questionable. Treatment with alloSCT should be reconsidered even more in the presence of other risk factors like increased comorbidity, as OS after alloSCT is very poor in these patients. On the other hand, because no studies have been performed comparing alloSCT vs no alloSCT directly in this high-risk patient group, a potential slight benefit cannot be captured in a HR. It may be possible that a very limited number of MDS patients with chromosome 7 abnormality and additional MK may still benefit from alloSCT, as in the case of AML, 45 where the HR for performing alloSCT is rather low compared with no alloSCT. Because of the lack of prospective randomized clinical trials in this field, this view remains hypothetical.
There is clearly room for exploring more promising approaches for MDS patients with chromosome 7 abnormalities and additional MK. One example is the use of hypomethylating agents after relapse. 46 Another direction is the application of donorlymphocyte infusions (DLIs) in relapsed patients. Although only few seem to benefit from DLI as the exclusive treatment, 47 ,48 the use of preceding cytoreduction warrants further exploration. 49, 50 Another alternative might be to apply DLI in a preemptive setting before signs of relapse.
